{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-153429","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.108807+00:00","generated_at":"2026-05-18T09:56:52.922958+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apellis enters $275M royalty buy-down with Sobi; reduces Aspaveli royalties 90%","bullets":["Sobi pays Apellis $275M upfront; up to $25M more on EMA approval of Aspaveli for C3G and IC-MPGN.","Royalty obligations under Collaboration Agreement reduced by 90% from closing, subject to cap of 1.45x payments made.","Sixth Street lenders consent to deal; Apellis extends prepayment premium periods on credit facility by one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-153429","json":"https://secwatch.observer/filing/0001193125-25-153429.json","markdown":"https://secwatch.observer/filing/0001193125-25-153429.md","text":"https://secwatch.observer/filing/0001193125-25-153429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312525153429/0001193125-25-153429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312525153429/d940210d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:56:52.922958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}